

**1) General Information****Heidel, Florian, MD, Professor**

Director and Chair, Internal Medicine C, Hematology, Oncology, Stem Cell Transplantation and Palliative Care, University Medicine Greifswald, Sauerbruchstr, 17475 Greifswald, Germany  
(e) [florian.heidel@med.uni-greifswald.de](mailto:florian.heidel@med.uni-greifswald.de) (ph) +49-3834 86-6698

**2) Academic Education**

**10/96-10/02** Medical School, Friedrich-Alexander University Erlangen

**3) Scientific and Academic Degrees**

**11/14** Board Certification Hematology and Oncology  
**12/12** Venia legendi for Internal Medicine, Otto-von-Guericke University Magdeburg  
**12/08** Board Certification Internal Medicine  
**05/03** Doctoral Thesis (M.D.), Friedrich-Alexander-University Erlangen (Prof. R. Marschalek)  
**10/02** Approbation / State Exam

**4) Professional Career**

**Since 10/20** W3 Professor & Director, Internal Medicine C, University Medicine Greifswald  
**04/16-09/20** Deputy Director, Internal Medicine II, Hematology/Oncology, University Hospital Jena  
**12/15-09/20** W2-Professor, Medical Faculty, Friedrich-Schiller University Jena and Research Group Leader (Collaborative Research Group), Leibniz Institute on Aging, Jena, Germany  
**2012-2015** Junior Research Group Leader and Staff (Oberarzt), Hematology and Oncology, Otto-von-Guericke-University Magdeburg (since 2013 Project Leader SFB854/2)  
**2009-2012** Post-Doctoral Research Fellow, Dana Farber Cancer Institute, Harvard University, Boston, USA (Laboratory of Prof. S. A. Armstrong, MD, PhD)  
**2002-2008** Residency/Fellowship (Internal Medicine, Hematology and Oncology), JGU Mainz, Germany

**5) Honors, awards**

**04/16** Karin-Nolte-Award (SPIG)  
**11/13** Langener Wissenschaftspreis of the Paul-Ehrlich-Institut (PEI)  
**06/13** Research Fellowship Award, European Hematology Association (EHA)  
**11/12** Hexal-Award (Magdeburg University, Hexal Inc.)  
**11/11** TRTH (Translational Research Training in Hematology) Participant 2012, EHA/ASH

**6) Scientific activities**

Since **2020** Member of the Fachkollegium Hämatologie, Onkologie, Transfusionsmedizin (DFG)  
Since **2020** Member of the Fachausschuss Wiss. Nachwuchsförderung (Deutsche Krebshilfe e.V.)  
Since **2017** Steering Committee Member, German MPN Study Group (GSG-MPN)

**7) Publications (5 selected of last 5 years)**

Jayavelu AK\*, Schnöder TM\*, Perner F, Herzog C, Meiler A, Krishnamoorthy G, Huber N, Mohr J, Edelmann-Stephan B, Austin R, Brandt S, Palandri F, Schröder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hübner CA, Zeiser R, Rahmig S, Waskow C, Coldham I, Ernst T, Hochhaus A, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M, and **Heidel FH**. Splicing factor Ybx1 mediates persistence of Jak2-mutated neoplasms. **Nature**. 2020 Dec;588(7836):157-163. doi: 10.1038/s41586-020-2968-3. PMID: 33239784

Saliakoura M, Pozzato C, Rossi MS, **Heidel FH**, Schnöder TM, Baumgartner J, Freigang S, Rimessi A, Pinton P, Felser AD, Nuoffer JM, Spasenija SP, Bubendorf L, Schmid R, Berezowska SA, and Konstantinidou G. PLCgamma1 inhibition mediates the survival of KRAS-mutant lung cancer during hypoxia. **Nat Cell Biol**. 2020 Nov;22(11):1382-1395. doi: 10.1038/s41556-020-00592-8. Epub 2020 Oct 19. PMID: 33077911

Mohr J, Dash BP, Schnoeder TM, Wolleschak D, Herzog C, Tubio Santamaria N, Weinert S, Godavarthy S, Zanetti C, Naumann M, Hartleben B, Huber TB, Krause DS, Kähne T, Bullinger L, **Heidel FH**. The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function. **Leukemia** 2018 May;32(5):1211-1221.

Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, **Heidel FH**, Kröger N, Triviari I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R. Oncogenic JAK2<sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. **Sci Transl Med**. 2018 Feb 21;10(429).

Perner F, Schnöder TM, Ranjan S, Wolleschak D, Ebert C, Pils MC, Frey S, Polanetzki A, Fahldieck C, Schönborn U, Schraven B, Isermann B, Fischer T, **Heidel FH**. Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function. **Leukemia**. 2016 30: 991-995.